PARTNERING
Partnering is the key enabler for our 2030 ambition and beyond.
Our partnership strategy is driven by a single objective: accelerate the development of transformative treatments that significantly improve patient lives. We believe in a people-oriented approach to our partnerships, focusing on mutual value creation by combining our collective expertise.
As part of our 2030 ambition, we are focusing on strategic partnerships and programmatic deal-making, mainly in oncology and neurology. We aim to drive innovation by working closely with our partners to make a meaningful impact on patient lives.
In oncology, we primarily focus on opportunities from early-stage to late-stage programs in:
In neurology, we are primarily interested in rare neurological disorders at pre-clinical and clinical stages, such as:
We also have partnering interests in cardiometabolism & venous diseases (commercial stage assets), digital health solutions, and a range of therapeutic modalities and technologies including Data & AI.
We would welcome a discussion with interested parties.
At Servier, we have the resources and reach of a globally established pharmaceutical company combined with a long-term vision focused on developing transformative medicines for patients. Our unique value proposition enables us to build successful partnerships.
Partnering is the key enabler for our 2030 ambition and beyond.
Servier To Acquire a Potential Best-in-Class Precision Therapy for Acute Leukemias, from BioNova Pharmaceuticals
Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy
Servier completes acquisition of Agios Pharmaceuticals’ oncology business
The start-up incubator Spartners by Servier & BioLabs, housed within our R&D Institute in Paris-Saclay, is unique in France. Operated by BioLabs, the leader in shared laboratories, the incubator is designed to accommodate around 15 start-ups, or over 100 scientists, within a 1,850 sqm building and located in one of the major European ecosystems.
Spartners by Servier & BioLabs offers shared or private laboratories, fully equipped with state-of-the-art facilities, enabling selected residents to work independently and benefit from the best equipment to accelerate their development.
Do you want to join the incubator? Learn more about Spartners by Servier & BioLabs
Participate in the Golden Ticket competition for start-ups and biotechs
The Golden Ticket serves as a bridge between start-ups and the global pharmaceutical ecosystem, stimulating scientific innovation for the benefit of patients. Winning start-ups join an incubator for one year, providing them with all the resources needed to pave the way for new therapies, particularly in oncology and neurology.
Find out more about the Golden Ticket: accelerating start-up innovation for the benefit of patients
Since 2017, Servier has awarded an annual Golden Ticket with LabCentral in the Boston-Cambridge ecosystem. In 2024, this expanded to France with BioLabs, and in 2025, to the Nordic countries with SmiLe Venture Hub, recently ranked among “Europe’s Leading Start-up Hubs 2024”1 by the Financial Times.
Paris-Saclay: Our incubator is opening its doors!
Golden Ticket: Fast-tracking start-up innovation to benefit patients
Partnering Day and Golden Ticket in Malmö: A day dedicated to open innovation for patients
*Oncology:
Leukemia: AML: Acute Myeloid Leukemia, ALL: Acute Lymphoblastic Leukemia, MDS: Myelodysplastic syndromes, MPN: Myeloproliferative neoplasms
GI (Gastro-intestinal) includes: PDAC: Pancreatic Ductal Adenocarcinoma, CRC: Colorectal Cancer, BTC: Biliary tract cancers, PaCa: Pancreatic Cancer, small intestine, anal, appendiceal.
Other non-core solid tumors including but not limited to: Gyn, GU, H&N, thyroid, thymoma.
Neurology:
Rare movement disorders – FA: Friedreich Ataxia; SCA: Spinocerebellar Ataxia; MSA: Multiple system Atrophy; PSP: Progressive Supranuclear Palsy; HD: Huntington Disease.
Neuromuscular disorders – ALS: Amyotrophic Lateral Sclerosis; SMA: Spinal Muscular Atrophy; DMD: Duchene Muscular Atrophy; FSHD: Fascioscapulohumeral Dystrophy; DM: Myotonic Dystrophy; MG: Myasthenia Gravis.
Refractory epilepsies – DS: Dravet Syndrome; LGS: Lennox-Gastaut Syndrome; JS: Jeavons Syndrome; WS: West Syndrome; DEE: Developmental and Epileptic Encephalopathies.
Modalities: mAb: monoclonal Antibodies ADC: Antibody Drug Conjugates
[1] https://rankings.ft.com/incubator-accelerator-programmes-europe/ranking/europes-leading-start-up-hubs, consulted on 05/05/2025